NVONVO
US • —
$49.29
P/E
1.80
PEG
0.11
FCF Yield
—
Rev Growth YoY
+8.1% YoY
Gross Margin
81.8%
Health Score
6/10
D/E Ratio
0.67
Confidence
LOW
Business Snapshot
Novo Nordisk is a global healthcare company primarily focused on diabetes care, obesity treatment, and other chronic diseases. The company operates in the large and growing metabolic disease market, where it holds a dominant competitive position as a leader in GLP-1-based therapies. The market capitalisation is not available in this data set. The company’s defining characteristic is its strong market position in the GLP-1 drug class, which has driven significant revenue and profit growth for the company.
Financial Health
Gross margin stands at a very high 81.8%, and net margin is also robust at 37.2%. The balance sheet appears healthy with a low Debt/Equity ratio of 0.67x, though the Current ratio of 0.8x suggests that current liabilities slightly exceed current assets, which is a minor liquidity concern for some investors...
Risk Assessment
- LIQUIDITY — Current ratio of 0.8x is below the 1.0x threshold, indicating that current liabilities exceed current assets.
- EARNINGS CREDIBILITY — The company has only beaten earnings estimates in 2 out of the last 4 quarters, offering mixed signals on management's ability to consistently exceed expectations.
- VALUATION DIVERGENCE — The P/E ratio of 1.8x and Price/Sales of 4.26x present conflicting signals on how the market values the company's earnings versus its revenue.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed....
Gross margin stands at a very high 81.8%, and net margin is also robust at 37.2%. The balance sheet appears healthy with a low Debt/Equity ratio of 0.67x, though the Current ratio of 0.8x suggests that current liabilities slightly exceed current assets, which is a minor liquidity concern for some investors. Free cash flow data is unavailable, preventing a full assessment of cash generation. Return on equity is exceptionally high at 66.4%, indicating very efficient use of shareholder capital. Overall, the company shows strong profitability and manageable debt, but the lack of free cash flow data and the sub-1.0 current ratio temper the assessment of financial flexibility.
- LIQUIDITY — Current ratio of 0.8x is below the 1.0x threshold, indicating that current liabilities exceed current assets. - EARNINGS CREDIBILITY — The company has only beaten earnings estimates in 2 out of the last 4 quarters, offering mixed signals on management's ability to consistently exceed expectations. - VALUATION DIVERGENCE — The P/E ratio of 1.8x and Price/Sales of 4.26x present conflicting signals on how the market values the company's earnings versus its revenue. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives